33422-35-4

Usage

Uses

Used in Pharmaceutical Research and Development:
ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE is used as a precursor in the synthesis of various pharmaceuticals for its ability to contribute to the development of drugs with diverse therapeutic applications.
Used in Antiviral Applications:
ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE is used as an antiviral agent for its potential to inhibit viral replication and reduce the severity of viral infections.
Used in Antibacterial Applications:
ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE is used as an antibacterial agent to combat bacterial infections and reduce the risk of antibiotic resistance.
Used in Antifungal Applications:
ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE is used as an antifungal agent to treat fungal infections and prevent the growth of fungi.
Used in Neurological Disorder Treatment:
ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE is used as a potential therapeutic agent for the treatment of neurological disorders, leveraging its neuroprotective and neuroregenerative properties.
Used in Anti-inflammatory Applications:
ETHYL 2-(3-OXO-2-PIPERAZINYL)ACETATE is used as an anti-inflammatory agent to reduce inflammation and alleviate symptoms associated with inflammatory conditions.

InChI:InChI=1/C8H14N2O3/c1-2-13-7(11)5-6-8(12)10-4-3-9-6/h6,9H,2-5H2,1H3,(H,10,12)/p+1/t6-/m1/s1

Upstream product

• 107-15-3 ethylenediamine 
• 141-05-9 Diethyl maleate 
• 623-91-6 diethyl Fumarate 

Downstream Products

• 104143-60-4 4-acetyl-3-carbethoxymethylpiperazin-2-one 
• 129355-66-4 [1-(2-Fluoro-benzoyl)-3-oxo-piperazin-2-yl]-acetic acid ethyl ester 
• 129355-67-5 [1-(2,6-Difluoro-benzoyl)-3-oxo-piperazin-2-yl]-acetic acid ethyl ester 
• 129355-68-6 [3-Oxo-1-(2-trifluoromethyl-benzoyl)-piperazin-2-yl]-acetic acid ethyl ester 
• 129355-64-2 1-bromoacetyl-3-oxo-1,4-piperazine-2-acetic acid ethyl ester 
• 153894-17-8 8-benzylperhydropyrazino<1,2-d><1,4>diazepine 
• 153894-16-7 8-benzylperhydropyrazino<1,2-d><1,4>diazepine-1,6,9-trione 
• 153894-15-6 1-benzylaminoacetyl-2-carbethoxymethylpiperazin-3-one 
• 61155-09-7 (1-benzyl-3-oxo-piperazin-2-yl)-acetic acid ethyl ester 
• 3388-79-2 2-(2-hydroxyethyl)piperazine 
• 936940-62-4 3-(2-hydroxyethyl)piperazin-2-one 
• 917572-18-0 ethyl {1-[1-(diphenylmethyl)azetidin-3-yl]-3-oxopiperazin-2-yl}acetate 
• 318469-54-4 ethyl 2-(1-(2,4-dichlorophenylsulfonyl)-3-oxopiperazin-2-yl)acetate 

Relevant academic research and scientific papers

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer

Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to formula I pharmaceutical compositions comprising them, a process for preparing them, and the use of such compounds to treat or inhibit pain and other disorders or disease states.

NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

Acetylcholine receptor ligands of formula I wherein D, E and G are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the sam

NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

Acetylcholine receptor ligands of formula (I), wherein D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for usi

BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID AND CYCLIC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS

This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.

Synthesis of Perhydropyrazinodiazepine, a New Heterocyclic Compound

A novel heterocycle, perhydropyrazinodiazepine, is prepared in good yield by an efficient method starting from facile available compounds.

Synthesis and biological activity of a series of aspartate transcarbamoylase inhibitors: N-substituted diethyl aspartates and N-substituted-3-oxo-1,4-piperazine-2-acetic acid esters

Series of N-substituted diethyl aspartates and N-substituted-3-oxo-1,4-piperazine-2-acetic acid esters were synthesized as potential inhibitors of aspartate transcarbamoylase. The aspartates were obtained by addition of substituted alkyl amines to diethyl